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Introduction {#sec1}
============

Mouse embryonic stem cells (ESCs) from early-stage embryos have indefinite self-renewal capacity and can differentiate into cell types derivative of all three germ layers through asymmetric cell division ([@bib34]). Asymmetric cell division is a complex process whereby transcription, cell differentiation, cell cycle, and cell polarity must be coordinated in time and space ([@bib36]). In vitro embryoid bodies (EBs) are powerful tools with which to study and understand the molecular mechanisms that underlie this process, as they mimic the in vivo developmental stages of peri-implantation embryos from epiblast to egg cylinder stages. An early step in this process is formation of the primitive endoderm (PE), an outer layer of polarized cells, followed by epiblast and primitive ectoderm development ([@bib35]).

Genome-wide screens have identified many potential regulators of stem cell function. These include genes with established roles in transcription regulation, cell growth, and differentiation, as well as genes whose function is largely unknown or remains to be validated in the context of stem cell biology, including the *Dido* (death inducer obliterator) gene ([@bib24], [@bib23], [@bib7], [@bib5]).

We identified *Dido*, a complex gene that encodes three proteins generated by alternative splicing. From smallest to largest, these isoforms are DIDO1, DIDO2, and DIDO3; they have a common N-terminal region and isoform-specific C-terminal parts ([@bib14]). DIDO3 composition, as determined by bioinformatics analysis, suggests that it helps maintain genomic stability ([@bib42]). DIDO3 comprises a plant homeodomain (PHD) finger, a transcription elongation factor S-II subunit M (TFSIIM) domain, a Spen paralog and ortholog (SPOC) module, and a long C-terminal region (CT) of unknown homology ([@bib42], [@bib14]). The exact functions of DIDO3 TFSIIM and SPOC modules have not yet been defined. In the TFIIS transcription elongation factor, the TFSIIM domain binds to and facilitates RNA polymerase II activity ([@bib22]); the SPOC module is linked to Spen family proteins, which are involved in transcriptional repression ([@bib46]). The PHD, one of a large group of zinc-finger proteins, recognizes post-translationally modified histone tails, including methylated lysine residues ([@bib32]).

We determined the crystal structure of the DIDO PHD finger in complex with histone 3 trimethylated on lysine 4 (H3K4me3), which showed an atypical aromatic cage-like binding site bearing a histidine residue. Biochemical, structural, and mutational analyses of this complex identified specificity and affinity determinants for DIDO PHD binding, which is disrupted by threonine 3 phosphorylation and triggers DIDO3 translocation from chromatin ([@bib18]).

DIDO1 localizes in the nucleus and cytosol, whereas DIDO2 is found only in the nucleus ([@bib14]). DIDO3, located primarily in the nucleus and centrosomes ([@bib49]), is expressed strongly in ESCs and decreases during development; expression is weaker in somatic cells, but recovers in induced pluripotent stem cells generated from somatic cells ([@bib18]).

All attempts to date to delete DIDO in cell lines or in mice show that deletion is incompatible with life. N-terminal truncation of DIDO (*DidoΔNT*) provokes aneuploidy, centrosome amplification, and DNA damage in the form of centromere-localized breaks ([@bib19]), and leads to chromosomal instability ([@bib29], [@bib49]). Mice with the *DidoΔNT* mutation show hematological myeloid neoplasms, and alterations in DIDO are associated with the myelodysplastic syndrome in humans ([@bib14]). Characterization of *DIDO* isoform expression in myeloproliferative neoplasms showed no *DIDO2* expression differences in CD34^+^ hematopoietic stem cells from polycythemia vera, essential thrombocythemia, and primary myelofibrosis patients. In contrast, *DIDO2* expression is high in advanced phases of chronic myeloid leukemia ([@bib4]), suggesting that DIDO2 contributes to this disease.

DIDO3 has a role in delivery of actin-dependent histone deacetylase 6 (HDAC6) to the primary cell cilium ([@bib45]). HDAC6 counteracts the activity of α-tubulin acetyltransferase (ATAT1) ([@bib9]), which acetylates TUBULIN and thus stabilizes primary cilium architecture.

In a second mutation (*Dido3ΔCT*), we replaced the *Dido3*-specific last exon, which encodes its C terminus and includes the centrosomal targeting domain ([@bib45]). Deletion of this region leads to embryonic lethality; embryos die by gestation day 8.5 ([@bib15]). ESCs derived from *Dido3ΔCT* mutant embryos do not differentiate correctly after aggregation and leukemia inhibitory factor (LIF) withdrawal, but retain their capacity for self-renewal, as shown by sustained expression of OCT4 and other markers of undifferentiated stem cells. Differentiation can be recovered in vitro by reconstitution with full-length DIDO3, retinoic acid (RA) treatment, or in the teratoma assay ([@bib15]). Ectopic expression of the common DIDO NT region in *Dido3ΔCT* cells downregulates stemness genes in EBs only when the wild-type (WT) PHD is present ([@bib18]). In vivo differentiation can be rescued by crossing *Dido3ΔCT* with the *DidoΔNT* mutant. These double mutants overcome embryonic lethality, although the mice suffer high perinatal mortality and neurodevelopmental, morphogenetic, and metabolic alterations ([@bib50]).

The DIDO1 isoform is upregulated when pro-B cells differentiate in vitro after growth factor starvation; its cytoplasmic localization requires phosphorylation and must be dephosphorylated for nuclear translocation ([@bib16], [@bib17]). DIDO1 is also upregulated during WT ESC differentiation after LIF withdrawal and aggregation to EBs; this upregulation fails in mutant *Dido3ΔCT* ESCs ([@bib15], [@bib18]).

Here we show an essential role for DIDO3 and DIDO1 isoforms at the onset of ESC differentiation. DIDO3 binds to its own promoter, associates with RNA polymerase II (RNA POL II), and regulates *Dido1* transcriptional activation; after binding to the H3K4me3 domain, DIDO1 helps to downregulate stemness genes and upregulate genes associated with ESC differentiation. Atypical protein kinase C (aPKC) phosphorylates the NT domain; in DIDO1, this causes its translocation to the outer layer of PE cells, where it associates with WWP2, an E3 ubiquitin-protein ligase, to promote degradation of OCT4, the master regulator of stemness. In DIDO3, this phosphorylation triggers translocation to the centrosome and promotes correct centrosome positioning. We describe a model by which, in ESC, self-regulating *Dido* splice variants participate in the early stages of developmentally controlled gene expression patterns that determine cell self-renewal versus differentiation.

Results {#sec2}
=======

Functional Effect of DIDO Domains on Regulation of Stemness Gene Expression {#sec2.1}
---------------------------------------------------------------------------

*Dido3ΔCT* ESCs are unable to differentiate correctly, and can serve as a model to study stem cell self-renewal and differentiation ([@bib15]). Here we used Agilent microarrays to compare transcriptomes of 10-day EBs (d10EBs) from WT and *Dido3ΔCT* cells. Gene ontology (GO) analysis showed persistent expression of stemness-related genes and genes involved in transcription regulation, and lack of genes associated with differentiation of all three germ layers ([Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}).

To test the influence of distinct DIDO regions ([Figure S2](#mmc1){ref-type="supplementary-material"}A), we expressed the common N-terminal part of DIDO (HA-DIDONT) or the missing specific C-terminal part of DIDO3 (HA-DIDO3CT) in *Dido3ΔCT* ESC, and compared the d10EB gene expression profile with that of WT EB. Ectopic HA-DIDONT expression partially restored gene expression to the WT EB pattern. As predicted from previous results, HA-DIDONT EBs recovered downregulation of stemness genes ([@bib18]) and expression of a subset of other genes; GO analysis indicated that these genes are involved in endoderm and mesoderm differentiation ([Figures 1](#fig1){ref-type="fig"}A and 1B). Genes associated with ectoderm differentiation were not rescued ([Figure S1](#mmc1){ref-type="supplementary-material"}; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}). In contrast, stemness-related genes were not downregulated by ectopic HA-DIDO3CT expression, and endoderm- and mesoderm-related gene expression were only partially restored ([Figures 1](#fig1){ref-type="fig"}A and 1B). Although the WT DIDO PHD domain is necessary for the restoration effect by the NT region ([@bib18]), it is not sufficient, as the NT must localize to the nucleus. In a mutant lacking the nuclear localization domain (HA-DIDONTΔNLS), the protein remained in cytoplasm ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and d10EBs showed no decrease in stemness-related genes ([Figure S2](#mmc1){ref-type="supplementary-material"}C). These findings show the distinct effect of DIDONT and DIDO3CT domains on ESC differentiation, which led us to analyze the implication of the DIDO1 and DIDO3 isoforms in differentiation.

DIDO1 and DIDO3 Expression in Early ESC Differentiation Stages {#sec2.2}
--------------------------------------------------------------

In floating culture conditions, ESC aggregation to form EBs accompanied by LIF withdrawal leads EBs to mimic the early steps of in vivo cell differentiation ([@bib10], [@bib11]). By day 3--4, the outer cell layer of WT EB forms the PE, characterized by expression of endoderm markers such as GATA4 and by downregulation of OCT4, a major component of the ESC circuit responsible for self-renewal ([@bib20], [@bib35]) ([Figure 2](#fig2){ref-type="fig"}A). Affymetrix microarray analysis showed differential gene expression between WT and *Dido3ΔCT* ESC. *Dido1* expression was 2.8-fold lower in *Dido3ΔCT* compared with WT ESCs (see [Table S3](#mmc4){ref-type="supplementary-material"} for full microarray data). At variance with WT EBs, *Dido3ΔCT* EBs did not correctly develop the PE cell layer ([Figure 2](#fig2){ref-type="fig"}A; [@bib15]) or induce increased *Dido1* expression ([@bib18]). We monitored DIDO1 and DIDO3 levels in WT d4EBs using antibodies to peptides of the specific DIDO1 or DIDO3 CT domains (PAB-DIDO1 and PAB-DIDO3) ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Whereas DIDO3 was expressed mainly in the nucleus, DIDO1 was found at the apical site of the PE cells, with weak nuclear expression ([Figure 2](#fig2){ref-type="fig"}B). Staining with the monoclonal MAB-1C6 antibody (generated against amino acids 2--90 of the common NT region) ([Figure S2](#mmc1){ref-type="supplementary-material"}A) also showed DIDO nuclear staining, with faint expression at the apical membrane and limited co-localization with PAB-DIDO1 (see below).

A time-course analysis of DIDO1 expression during EB differentiation showed that, in contrast to *Dido3ΔCT*, WT EBs showed prominent apical membrane localization in PE cells starting at day 3 and persisting to day 4 ([Figure 2](#fig2){ref-type="fig"}C).

DIDO1 Is Essential for PE Development during EB Differentiation {#sec2.3}
---------------------------------------------------------------

To clarify the role of DIDO1 in ESC differentiation, we generated various WT ESC clones in which DIDO1 expression was inhibited by RNAi. Specificity control by RT-PCR showed a decrease in *Dido1*, but not in *Dido2* or *Dido3* RNA expression compared with small hairpin RNA (shRNA) *control*-infected cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A). DIDO1 protein reduction was also observed in cells expressing HA-DIDO1, as shown by western blot analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}B). shRNA-*Dido1* stable transfectants showed normal proliferation and self-renewal and were competent to form EBs. In contrast to shRNA-*control*, sh-*Dido1* EBs did not generate PE at day 4, as determined by absence of the PE markers GATA4 and FOXA2, OCT4 persistence ([Figure 3](#fig3){ref-type="fig"}A), and no apparent signs of differentiation beyond day 7 ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Moreover, RA treatment, which rescues PE formation and differentiation of *Dido3ΔCT* EBs ([Figure 3](#fig3){ref-type="fig"}B), failed to do so in shRNA-*Dido1* EBs ([Figure 3](#fig3){ref-type="fig"}C); FOXA2 staining was observed only inside the EBs and was independent of PE formation, as for WT EBs ([Figure 3](#fig3){ref-type="fig"}C).

DIDO1 upregulation and its apical expression in PE outer layer cells with concomitant OCT4 downregulation appeared to be essential during *Dido3ΔCT* EB differentiation induced by RA treatment or ectopic expression of HA-DIDO3 ([Figure 3](#fig3){ref-type="fig"}B). We also generated stable *Dido3ΔCT* ESC transfectants expressing HA-DIDO1, which proliferated normally in self-renewal conditions and showed no signs of differentiation (not shown). In the absence of LIF, EBs derived from these cells were able to reconstitute PE formation completely. In control staining, anti-HA and anti-DIDO1 antibodies co-localized at the inner PE cell membrane, where DIDO1 is also located in WT EBs ([Figure 3](#fig3){ref-type="fig"}D).

Using qRT-PCR low-density arrays of representative genes related to undifferentiated stem cells or to differentiation to the three germ layers, we found that shRNA-*Dido1* EBs do not differentiate in vitro ([Figure S4](#mmc1){ref-type="supplementary-material"}D). The gene expression pattern resembled that for *Dido3ΔCT* EBs ([Figure S4](#mmc1){ref-type="supplementary-material"}E).

These data indicate that EBs require DIDO1 to generate the PE outer cell layer and initiate ESC differentiation. Furthermore, DIDO1 must translocate from the nucleus to cytoplasm for correct PE formation.

DIDO3 Regulates Cell Polarization and DIDO1 Acts as a Cell Lineage Marker during Asymmetric ESC Division {#sec2.4}
--------------------------------------------------------------------------------------------------------

During ESC differentiation, a hallmark of differentiated PE cells is their apico-basolateral polarity ([@bib12]). To identify the role of DIDO in establishing polarization of the nascent PE layer in EBs, we used various polarization markers such as MEGALIN ([@bib31]), F-ACTIN, aPKC ([@bib2]), and acetylated TUBULIN ([@bib40]). In WT and shRNA-*control* EB, we confirmed PE cell polarization as detected by positive MEGALIN, F-ACTIN, and aPKC staining. We detected overlapping DIDO1 co-expression with these markers in the PE cell apical membrane. This was not the case in *Dido3ΔCT* or shRNA-*Dido1* EB, in which neither DIDO1 nor any of the polarization markers was found ([Figure 4](#fig4){ref-type="fig"}A). In the case of acetylated TUBULIN, expression was reduced only in *Dido3ΔCT* EB, whereas shRNA-*Dido1* EBs showed no difference compared with shRNA-*controls* ([Figure 4](#fig4){ref-type="fig"}A). These lower acetylation levels in *Dido3ΔCT* coincide with reported DIDO3 and HDAC6 association ([@bib45]).

As PE outer layer formation is impaired in *Dido3ΔCT* and shRNA-*Dido1* EBs, we could not determine whether DIDO1 was responsible for PE cell polarization or whether lack of PE cells defined the absence of DIDO1. To address this question, we used a culture model of ESC rosettes established in Matrigel, in which polarization in central lumen of rosettes is independent of PE formation ([@bib2], [@bib28]). WT ESCs growing in Matrigel without LIF expressed MEGALIN, F-ACTIN, aPKC, and acetylated TUBULIN in the rosette central lumen. In *Dido3ΔCT* ESC, rosette polarization was severely impaired, since \>60% of rosettes were abnormal, with aberrant staining patterns for all polarization markers including acetylated TUBULIN ([Figure 4](#fig4){ref-type="fig"}B). None of the rosettes from WT or *Dido3ΔCT* ESCs showed DIDO1 associated with polarization, which indicates that DIDO1 is dispensable in cell polarization.

Since TUBULIN acetylation has a role in microtubule dynamics and stabilization during cell polarization ([@bib30]), we studied microtubule and cytoskeleton organization in the rosettes. Based on quantification of acetylated and non-acetylated αβ-TUBULIN, we concluded that lower acetylated TUBULIN levels in *Dido3ΔCT* compared with WT rosettes and EBs were not the result of low TUBULIN levels ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Rosettes derived from *Dido3ΔCT*, in the presence of the HDAC6 inhibitors BML-281 ([@bib26]) or trichostatin A ([@bib40]), showed normal or even hyperacetylated TUBULIN compared with rosettes from WT ESCs ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Ectopic expression of HA-DIDO3, but not HA-DIDO1, completely normalized rosette polarization and TUBULIN acetylation in *Dido3ΔCT* rosettes, which showed that rescue of rosette polarization required DIDO3 but was less dependent on DIDO1 ([Figure 4](#fig4){ref-type="fig"}C). This polarization did not depend on DIDO1 or DIDO3 co-localization at the central lumen of rosettes ([Figure 4](#fig4){ref-type="fig"}D).

DIDO3 localizes to centrosomes and centrosomal organization is severely altered in *Dido* mutants ([@bib15], [@bib49]), especially in the *Dido3ΔCT* mutant, in which the centrosomal targeting domain is absent ([@bib45]). Since correct centrosome positioning is needed for single and central lumen initiation of rosettes ([@bib41], [@bib48]), we analyzed centrosome organization during polarization in early stages of rosette formation. Whereas at the 2-cell stage the large majority of centrosomes is correctly located in WT cells (\<6.7% ± 2.1% are incorrect), a substantial percentage of centrosomes was incorrectly located in *Dido3ΔCT* cells (28.3% ± 2.1%) ([Figure 4](#fig4){ref-type="fig"}E). This centrosome mislocation in *Dido3ΔCT* cells coincides with defective aPKC, αβ-TUBULIN, and F-ACTIN expression as well as of EZRIN, a marker of lumen formation ([@bib48]) ([Figure S5](#mmc1){ref-type="supplementary-material"}C).

These findings clearly show the relevance during cell polarization of DIDO3 compared with DIDO1, probably due to its centrosomal location; centrosome misplacement in the *Dido3ΔCT* ESCs thus leads to formation of abnormal rosettes.

Translocation of DIDO1 to Cytoplasm and DIDO3 to the Centrosome Requires Association with and Phosphorylation by PKCiota {#sec2.5}
------------------------------------------------------------------------------------------------------------------------

We found DIDO1 to be necessary for EBs to generate the PE outer cell layer, a process that requires DIDO1 translocation from the nucleus to cytoplasm. We identified DIDO1 at the PE cell apical membrane using the PAB-DIDO1 antibody, which recognizes phosphorylated and unphosphorylated DIDO1 forms. In EBs, the DIDONT-specific MAB-1C6 recognized DIDO1 and/or DIDO3 mainly in the nucleus, with faint expression at the PE inner membrane ([Figure 2](#fig2){ref-type="fig"}B). Epitope mapping and characterization of MAB-1C6 binding showed preferential reactivity with an unphosphorylated DIDO peptide ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). We conclude that DIDO1 must be phosphorylated to localize at the PE apical membrane, which coincides with the finding that cytoplasmic DIDO1 is phosphorylated ([@bib17]).

Tests for several markers on the polarized PE apical membrane showed localization of DIDO1 and aPKC (PKCiota and PKCzeta) ([Figure 4](#fig4){ref-type="fig"}A), both of which participate in cell polarization ([@bib43]). We analyzed the ability of both aPKCs to phosphorylate DIDO1 in an in vitro kinase assay with recombinant aPKC kinases that allow distinction between PKCiota and PKCzeta; as a substrate, we employed the same peptide used to characterize MAB-1C6 ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Mass spectrometry analysis ([@bib33]) showed that PKCiota phosphorylated the peptide at serine 8 ([Figure 5](#fig5){ref-type="fig"}A), as did PKCzeta to a lesser degree.

We tested whether recombinant PKCiota and/or PKCzeta phosphorylate WT HA-DIDONT, an HA-DIDONTSer8Ala mutant, or a shortened form of HA-DIDONT (cleaved at BglII) in an in vitro kinase assay with \[γ-^32^P\]ATP. PKCiota and PKCzeta both phosphorylated WT HA-DIDONT and HA-DIDONTSer8Ala; again, PKCiota phosphorylation was higher ([Figure 5](#fig5){ref-type="fig"}B). Only PKCiota phosphorylated the shortened HA-DIDONT(BglII), whereas PKCzeta did not ([Figure 5](#fig5){ref-type="fig"}B). The results show that PKCiota phosphorylates the DIDONT and that serine 8 is not the only phosphorylation site. A possible functional correlation of PKCiota and the DIDO protein is supported by the similarity between *Dido3ΔCT* mutant and PKCiota knockout mouse phenotypes, since both mutations result in early embryonic lethality ([@bib47]), and ESCs derived from either mutant embryo do not differentiate correctly in vitro.

Like DIDO3, aPKC localizes to centrosomes ([@bib1], [@bib43]), and DIDO3 is involved in organizing microtubules and polarization; we thus tested whether the DIDO3 NT region is also phosphorylated. Confocal analysis of 2-cell stage rosettes using PAB-DIDO3 and anti-γ-TUBULIN antibodies detected co-localization in the centrosome ([Figure 5](#fig5){ref-type="fig"}C). In contrast, MAB-1C6 and anti-γ-TUBULIN antibodies did not co-localize ([Figure 5](#fig5){ref-type="fig"}D), which suggests that centrosomal DIDO3 is also phosphorylated.

We concluded that phosphorylation of the DIDO1 and DIDO3 NT domains is a shared mechanism for DIDO translocation from the nucleus to cytoplasm (DIDO1) or to the centrosome (DIDO3), and suggest that the kinase PKCiota is involved in this process.

DIDO1 Interacts with WWP2 and Regulates OCT4 Degradation in PE Cells {#sec2.6}
--------------------------------------------------------------------

When cultured in Matrigel, blastocyst inner mass cells generate rosettes and a polarized outer endoderm layer ([@bib3]). In these conditions, ESC-derived rosettes form this PE layer, albeit at much lower efficiency, as defined by GATA4 and DIDO1 expression and OCT4 downregulation ([Figure S7](#mmc1){ref-type="supplementary-material"}A). As described above for EBs, we found no PE cell that co-expressed DIDO1 at the inner membrane and OCT4. Whereas OCT4 protein is not detected in these cells, they express *Oct4* RNA ([@bib20]), and OCT4 can be ubiquitinated by WWP2 ([@bib27], [@bib51]). We thus tested for DIDO1 and WWP2 expression in PE from WT EBs, and found that they co-localized in PE cells ([Figure 6](#fig6){ref-type="fig"}A).

A western blot time-course analysis to monitor WWP2 expression during WT ESC differentiation showed the highest WWP2 expression in ESCs, which decreased during differentiation ([@bib27]) ([Figure S7](#mmc1){ref-type="supplementary-material"}B). WWP2 expression was lower in *Dido3ΔCT* than in WT ESCs, and its modification and downregulation were delayed during EB differentiation ([Figure S7](#mmc1){ref-type="supplementary-material"}B). Using WWP2-specific antibody, we performed co-immunoprecipitation analyses in cells expressing HA-DIDO1, the HA-DIDONT domain, or HA-DIDO3CT. These studies confirmed interaction between HA-DIDO1 or HA-DIDONT and WWP2, whereas HA-DIDO3CT did not interact with WWP2 ([Figure 6](#fig6){ref-type="fig"}B). The results coincide with data in the BioGRID protein database that predict the DIDO and WWP2 interaction for *Homo sapiens*. Here we identify the DIDO NT domain as responsible for this interaction.

To define the cause of this WWP2/DIDO1 association, we used shRNA-*Wwp2* to inhibit WWP2 expression. Two representative clones were characterized as expressing different WWP2 levels ([Figure S7](#mmc1){ref-type="supplementary-material"}C). Whereas shRNA-*control* EBs showed the predicted PE cell formation pattern (expressing FOXA2 and DIDO1 but not OCT4), shRNA-*Wwp2* clone A (trace WWP2 expression) did not develop PE ([Figure 6](#fig6){ref-type="fig"}C); this phenotype resembled shRNA-*Dido1* ESC or *Dido3ΔCT* ESC differentiation to EBs. In shRNA-*Wwp2* clone B, we observed PE formation in ∼50% of EBs, with abnormal OCT4, DIDO1, and FOXA2 co-expression in these cells ([Figure 6](#fig6){ref-type="fig"}C). The results suggest that both DIDO1 and WWP2 are needed for correct PE formation, and that they associate and thus contribute to OCT4 ubiquitination and degradation.

DIDO3 Recruitment to Its Promoter and 3′ UTR Regions Regulates DIDO1 Expression {#sec2.7}
-------------------------------------------------------------------------------

Since ectopic DIDO3 expression rescues the ability of these EBs to differentiate by upregulating DIDO1, we analyzed the mechanism underlying this upregulation. From HA-DIDO3-expressing *Dido3ΔCT* ESC, we prepared chromatin immunoprecipitation sequencing (ChIP-seq) immunoprecipitates with anti-HA antibodies and sequenced bound DNA fragments. Bioinformatics analysis showed that HA-DIDO3 binds to its own genomic locus at least on three regions ([Figure 7](#fig7){ref-type="fig"}A and [Table S4](#mmc5){ref-type="supplementary-material"}) including the *Dido* proximal promoter, a site after the *Dido1* 3′ UTR region, and the *Dido3* 3′ UTR. The chromatin status of the *Dido* locus in mouse stem cells (data from Mouse ENCODE project; [@bib13]) confirmed *Dido* as an actively transcribed gene in ESCs, as indicated by H3K4me3 and H3K9ac at the distal and proximal *Dido* promoters. The active elongation histone mark H3K36me3 was positive, whereas the heterochromatic silencing markers H3K27me3 and H3K9me3 were absent ([Figure 7](#fig7){ref-type="fig"}A).

Although no DNA binding motif has so far been identified for DIDO, the PHD of the common NT region binds to H3K4me3 ([@bib18], [@bib39]). The peak detected in the proximal promoter is due to H3K4me3 binding, the only known binding site. There is no H3K4me3 at the second binding site (following the Dido1 3′ UTR), but rather H3K27ac, which is also present on both *Dido* promoters. This histone acetylation mark was described on poised enhancers that contribute to differentiation programs ([@bib8]). H3K27ac was not detected as a DIDO binding site, but DIDO association to HDAC might participate in the H3K27 acetylation status.

As the DIDO TSFIIM domain is linked to RNA POL II ([@bib42]) and the yeast DIDO3 homolog BYE1 binds RNA POL II ([@bib25], [@bib38]), we used co-immunoprecipitation experiments to test DIDO3 and DIDO3ΔCT association with RNA POL II. Both DIDO3 and DIDO3ΔCT associated with RNA POL II, which confirmed the link between DIDO and transcription ([Figure 7](#fig7){ref-type="fig"}B). When we included localization of RNA POL II, unphosphorylated or with various phosphorylation modifications (data from [@bib6]) in our representation of the *Dido* locus, we found RNA POL II peaks at DIDO3 ChIP-seq binding sites ([Figure 7](#fig7){ref-type="fig"}A).

To confirm DIDO3 and RNA POL II binding to the *Dido* locus, we performed further ChIP experiments followed by qPCR specific for the *Dido* proximal promoter and *Dido* internal binding site DNA, identified by ChIP-seq analysis. HA-DIDO3 (5.2-fold) and RNA POL II (6.5-fold) were enriched on the proximal promoter, as were HA-DIDO3 (3.8-fold) and RNA POL II (4.1-fold) on the internal *Dido* site ([Figure 7](#fig7){ref-type="fig"}C), which corroborates DIDO3 involvement in expression of *Dido* splice variants.

Discussion {#sec3}
==========

Advances in the identification and generation of stem cells from numerous organisms have produced vast knowledge in many fields including embryology and development. ESCs are capable of prolonged self-renewal in an undifferentiated state, but can also differentiate into several cell types. The molecular mechanisms that underlie these alternative processes remain to be identified, and appear critical for stem cell potential in regenerative/reparative medicine. Here we combined characterization of a stemness-associated locus (*Dido*) with the EBs' ability to mimic in vitro the early steps of in vivo ESC differentiation ([@bib10], [@bib11]).

ESC differentiation and formation of the PE cell layer require downregulation of stemness genes. In suspension culture, at 2--4 days after LIF deprivation, the polarized outer cell layer of EBs (the first cells to differentiate) forms the primitive endoderm, characterized by lack of stemness genes and expression of genes associated to the new PE cell fate. *Dido* is a gene complex that encodes three splice variants, *Dido1* (the smallest), *Dido2*, and *Dido3* (the largest) ([Figure S3](#mmc1){ref-type="supplementary-material"}). We show that the DIDO1 isoform is a central player in regulating the EB switch from expansion to a differentiation/maintenance phase. During self-renewal, DIDO3 maintains stemness gene expression by binding to H3K4me3 and RNA POL II, and DIDO1 expression is repressed. Less is known of the role of DIDO2, the least-expressed isoform, which has only a few more amino acids than the DIDO3ΔCT mutant. We do not detect DIDO2 protein expression at differentiation onset, which is associated with changes in DIDO3/DIDO1.

Cell differentiation requires DIDO1 in cytoplasm and in the nucleus, where it probably competes with DIDO3 for binding to H3K4me3, promoting downregulation of stemness genes and DIDO3 degradation. Through its nuclear export signal, DIDO1 is exported to cytoplasm, which depends on its association to and phosphorylation by PKCiota ([Figure 5](#fig5){ref-type="fig"}). Once in the cytoplasm, DIDO1 associates to the E3 ubiquitin-protein ligase (WWP2), which leads to OCT4 ubiquitination and degradation ([Figure 6](#fig6){ref-type="fig"}). PKCiota also associates to and phosphorylates DIDO3 to form a complex that regulates correct centrosome positioning in daughter cells. DIDO3 interaction with HDAC6 ([@bib45]) regulates TUBULIN acetylation, critical for its stabilization and dynamics ([Figure 4](#fig4){ref-type="fig"}). Both centrosome positioning and microtubule dynamics participate in the polarity pathway that controls stem cell self-renewal versus differentiation.

A model emerges in which DIDO acts as a switchboard that regulates a genetic program that drives stem cells between the transcription "modes" that operate to maintain pluripotency or promote differentiation. In these modes, control of the expression and cellular localization of different DIDO splice forms appears to be important. Whereas DIDO1 expression and phosphorylation commit cells to the first step in ESC differentiation, DIDO3 phosphorylation promotes its translocation to the centrosome, whose position it controls for the renewal or differentiation capacities of daughter cells.

Alternative mRNA isoforms are an important means of diversifying protein behavior, and have contributed to the complexity of vertebrate organisms ([@bib44]). Here we show that two *Dido* isoforms generated by differential splicing are critical to determination of cell lineage early in ESC differentiation. Self-renewal and differentiation events apparently have distinct genetic requirements in the transcription modes for pluripotent ESCs and for differentiating cells, which must integrate all signals needed for each stage.

DIDO1 and DIDO3 have several mechanisms that might take part in the pluripotent and somatic cell transcription modes and in development. The composition of DIDO isoform domains might aid in establishing these modes. DIDO1 has the PHD, whereas DIDO3 encodes a much larger protein with three signature motifs, PHD, TFS2M, and SPOC, all typically found in proteins involved in transcription regulation. We found that DIDO3 binds RNA POL II and thus links DIDO to transcriptional control, as shown for the yeast DIDO homolog BYE1 ([@bib25], [@bib38]). We show a direct DIDO3 role in regulating its own expression and that of DIDO1, as the *Dido3ΔCT* loss-of-function mutation confers a cell phenotype similar to that seen when DIDO1 is misregulated. ChIP mapping of DIDO3 recruitment to the *Dido* locus also indicated a binding pattern associated with a region that includes, but is not limited to, the *Dido* promoter ([Figure 7](#fig7){ref-type="fig"}). Results from chromatin binding indicated that DIDO3 binding to its own genomic DNA modulates *Dido1* expression and might participate in regulating core stemness genes, a question currently under study. These findings coincide with the role of d(PPS), the DIDO homolog in *Drosophila*. d(PPS) protein also has four signature motifs typically found in proteins that act in transcriptional regulation; d(PPS) is needed to regulate *Sxl* (*sex-lethal*) splicing ([@bib21]) and DIDO3 is necessary for DIDO1 expression. Given the known d(PPS) splicing function, our data and the parallels with d(PPS) results suggest a role for DIDO in transcription control by splicing.

Experimental Procedures {#sec4}
=======================

Cell Culture and Transfection {#sec4.1}
-----------------------------

All experiments using animal materials were designed in compliance with European Union legislation and approved by the Committee for Ethics in Animal Experimentation of the Centro Nacional de Biotecnología (CNB/CSIC) (Proex 322/15).

Mouse ESCs were maintained in KO-DMEM (Gibco, Invitrogen) with 20% fetal calf serum, 1× Glutamax (Invitrogen), non-essential amino acids, 0.05 mM 2-mercaptoethanol, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 1,000 U/mL mouse LIF supplement (Millipore) on a layer of mitomycin C-treated mouse embryonic fibroblasts or gelatinized tissue culture plates.

EBs were formed and cultured in suspension conditions in low-attachment dishes in the same medium without LIF. Rosettes were formed in the same medium without LIF and 5% Matrigel (Becton Dickinson) on 8-well chamber slides (iBidi) coated with 25 μL of Matrigel per well for 3 days, or 1 day for 2-cell stages.

Cells were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocols. For overexpression experiments, *Dido1*, *Dido3*, or *Dido* fragments were cloned in mammalian expression vector pCAGG-HA-tagged *Dido*-IRES-puromycin resistance cassette.

For shRNA *Dido1* experiments, we used *Dido1*-specific and negative control GIPZ lentiviral particles (Thermo Scientific). For *Wwp2* shRNA, we used retroviral pGFP-V-RS vector with control or four different 29mer shRNAs to murine *Wwp2* (Origene). Stable transfectants were obtained in all cases by puromycin selection (1 μg/mL). For target sequences, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Immunofluorescence {#sec4.2}
------------------

ESC, EB, or rosettes were fixed in 4% formaldehyde, permeabilized with 0.2% NP-40, blocked with 1% BSA, and stained with primary (overnight, 4°C) and secondary antibodies (2 hr, room temperature) and DAPI (30 min, room temperature). For the list of antibodies, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

A Zeiss laser scanning confocal microscope was used for confocal microscopy; images were processed with ImageJ software (NIH).

Immunoprecipitation {#sec4.3}
-------------------

For co-immunoprecipitation, cells were lysed in NETN buffer (20 mM HEPES \[pH 7.5\], 300 mM NaCl, 0.5 mM EDTA, 10% glycerol, 0.5% NP-40) with protease inhibitor cocktail (Roche) and 1 mM PMSF; cells for immunoprecipitation were lysed in RIPA buffer with the same inhibitors. Lysates were immunoprecipitated with specific antibody (overnight, 4°C), followed by addition of magnetic beads (Dynabeads, Invitrogen) coupled to Protein A or Protein G1, depending on the species and isotype of the first capture antibody. Immunoprecipitates were washed six times and released from beads in sample buffer (10 min, 70°C).

Western Blot {#sec4.4}
------------

Samples were separated by 4%--10% SDS-PAGE depending on protein size, then transferred to nitrocellulose membrane (Bio-Rad), followed by western blot analysis with indicated antibodies. ECL solution (PerkinElmer) was used to visualize proteins.

Microarray and qRT-PCR {#sec4.5}
----------------------

Total RNA was prepared with TRIzol (Invitrogen) and used for qRT-PCR in low-density arrays (TaqMan mouse stem cell, Applied Biosystems) and microarrays. Samples were labeled and hybridized on the mouse genome 430 2.0 array (Affymetrix) or Mouse GE 4x44K v2 microarrays (Agilent); three biological replicates were used for all conditions.

For detailed methods, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Kinase Assay {#sec4.6}
------------

Purified immunoprecipitates (magnetic beads with bound anti-HA + HA-DIDO1 or anti-HA + HA-DIDONT fragments) were washed once in kinase buffer (50 mM Tris \[pH 7.5\], 20 mM MgCl~2~, 10 mM MnCl~2~). Labeling reactions were performed with 10 μL of precipitated mixture +10 μL of recombinant PKC +5 μL of ATP-mix (cold ATP +10 μCi \[γ-^32^P\]ATP) (30 min, 30°C), washed twice in kinase buffer, released in sample buffer (10 min, 70°C) and resolved on a gel. The gel was fixed in methanol/acetic acid, dried, and exposed to X-ray film. Enzymes used were recombinant human PKCiota (14-505, Merck Millipore; 0.5 μg/reaction) and recombinant human PKCzeta (14-525, Merck Millipore; 0.2 μg/reaction).

Phosphopeptide Analysis {#sec4.7}
-----------------------

Phosphopeptides were analyzed by liquid chromatography-tandem mass spectrometry ion trap, alternating collision-induced dissociation, and electron transfer dissociation fragmentation techniques. For details, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Chromatin Immunoprecipitation and qPCR {#sec4.8}
--------------------------------------

For ChIP, we used the MAGnify Chromatin Immunoprecipitation System (Invitrogen) according to the manufacturer's protocol, with overnight immunoprecipitate incubation at 4°C. Inputs and eluates were used for qPCR with SYBR Green in an ABI PRISM 7900HT PCR (Applied Biosystems); x-fold probe enrichment was calculated relative to immunoglobulin G control precipitates, normalized to inputs. For primers, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Chromatin Immunoprecipitation Sequencing {#sec4.9}
----------------------------------------

ChIP-seq was performed mainly as described by [@bib37]. In brief, HA-DIDO3-expressing *Dido3ΔCT* ESCs were 1% formaldehyde-fixed and lysed in lysis buffer with proteinase inhibitor cocktail (Roche) and PMSF. Chromatin was sonicated in a Diagenode Bioruptor; fragments of ∼200--500 base pairs (verified by gel) were diluted with RIPA buffer and precipitated with anti-HA polyclonal antibody (ChIP-grade, ab9110; Abcam) coupled to magnetic beads coated with anti-rabbit immunoglobulin (Invitrogen; overnight, 4°C). Beads were washed extensively, and the precipitates were eluted and reverse-crosslinked; the DNA was purified on Qiagen columns. Further processing and massive sequencing was performed by the Genomics Service Unit, Parque Científico de Madrid (see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

ChIP-Seq Analysis {#sec4.10}
-----------------

Mapped reads were aligned with the Bowtie program on the mouse genome (NCBI Build 37/UCSC mm9) and significant peaks identified using MACS software (v. 1.4) with default thresholds. For detailed procedures, see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Statistical Analysis {#sec4.11}
--------------------

Data are shown as mean ± SD. Statistical analyses were performed using Student's t test.
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![Functional Effect of DIDO Domain Expression in Day-10 Embryoid Bodies\
(A) Group of genes, determined in Agilent microarrays, whose expression recovered to WT levels only after HA-DIDONT region expression in *Dido3ΔCT* ESCs, and GO analysis terms with example genes.\
(B) Group of genes whose expression was fully recovered by HA-DIDONT and partially by the HA-DIDO3CT region, with GO analysis and example genes. All array data are from three biological replicates.](gr1){#fig1}

![DIDO1 and DIDO3 Expression in Early ESC Differentiation\
(A) Left: immunostaining of WT day-4 embryoid bodies (d4EBs) for OCT4 (green) and GATA4 (red); arrowheads mark outer primitive endoderm (PE) cell layer. Right: lack of PE formation in *Dido3ΔCT* d4EBs.\
(B) Left: localization of DIDO isoforms using anti-DIDO MAB-1C6 (green; mainly in nucleus) and DIDO3-specific PAB-DIDO3 (red). Right: localization of DIDO isoforms using MAB-1C6 (green) and DIDO1-specific PAB-DIDO1 (red; preferentially at the apical membrane of outer cell layer).\
(C) Left: developing PE and apical localization of DIDO1 (arrowheads) in a time course of WT d1--d4EBs labeled for OCT4 (green) and DIDO1 (red) expression. Right: lack of PE formation in a time course of *Dido3ΔCT* d1--d4EBs labeled for OCT4 (green) and DIDO1 (red).\
All panels are confocal images with nuclear counterstaining (DAPI, blue). Scale bars, 50 μm.](gr2){#fig2}

![DIDO1 Is Essential for PE Formation\
(A) (Left) shRNA-*Control* d4EBs with staining for PE formation (arrowheads). Top row: OCT4 (green; inside EBs), GATA4 (red; outer PE cells). Center: OCT4 (green; inside EBs) and DIDO1 (red; at apical membrane of outer PE cells). Bottom: DIDO1 (green; apical membrane) and FOXA4 (red; PE outer cell layer). (Right) All rows: lack of PE formation in shRNA-*Dido1* d4EBs.\
(B) (Left) Reconstitution of PE formation by ectopic HA-DIDO3 expression in *Dido3ΔCT* d4EBs; OCT4 (green; inside EBs) and DIDO1 (red; at apical membrane of PE cells). (Right) The same PE reconstitution pattern of *Dido3ΔCT* d4EBs after retinoic acid (RA) treatment.\
(C) Comparison of solvent (DMSO) versus RA-treated shRNA-*Co* d4EBs. (Left) Top: OCT4 (green; reduction inside EBs) and DIDO1 (red; at apical membrane of PE cells). Bottom: DIDO1 (green; at apical membrane of PE cells) and FOXA2 (red; arrowheads indicate PE outer layer in DMSO-treated cells and inside EBs in RA-treated cells). (Right) shRNA-*Dido1* d4EBs with lack of PE formation in DMSO- or RA-treated EBs, no DIDO1 labeling at apical membrane, and FOXA4 (red; only inside EBs).\
(D) Ectopic HA-DIDO1 expression of reconstituted PE formation in *Dido3ΔCT* d4EBs. (Left) OCT4 (green; inside EBs) and DIDO1 (red; on apical membrane of PE cells). (Right) Co-localization of anti-HA (green) and DIDO1 (red) at apical membrane of outer PE cells.\
Nuclei staining (DAPI, blue). Scale bars for EBs, 50 μm; Scale bar in boxed area of (D), 10 μm.](gr3){#fig3}

![DIDO3 Regulates Polarization and DIDO1 Regulates Fate of PE Cells\
(A) Left: comparison of WT and *Dido3ΔCT* d4EBs for apical polarization markers (MEGALIN, red; phalloidin-labeled F-ACTIN, red; aPKC, green; acetylated TUBULIN; green) and DIDO1 (green) at the PE layer (arrowheads). Right: comparison of shRNA-*control* and shRNA-*Dido1* d4EBs (staining as in left panel). Scale bars, 50 μm.\
(B) Left: WT rosettes stained for polarization markers as in (A) and DIDO1 for apical polarization at the central lumen (arrowheads). Right: examples of *Dido3ΔCT* rosettes with mislocalization of polarization markers; bottom row of rosettes stained with anti-αβ-TUBULIN (green). Nuclei (DAPI, blue). Scale bars, 20 μm.\
(C) Quantification of the percentage of polarized rosettes of WT, *Dido3ΔCT*, shRNA-*Co*, shRNA-*Dido1*, HA-DIDO1-reconstituted *Dido3ΔCT*, and HA-DIDO3-reconstituted *Dido3ΔCT*. Data are shown as mean ± SD (n from more than three independent experiments).\
(D) Left: acetylated TUBULIN (green) in *Dido3ΔCT* rosettes reconstituted with HA-DIDO1 or HA-DIDO3. Right: HA-DIDO3 (green) and DIDO1 (red) localization in HA-DIDO3-reconstituted *Dido3ΔCT* rosettes. Scale bars, 20 μm.\
(E) Position of centrosomes labeled with anti γ-TUBULIN (green) in WT (left) and *Dido3ΔCT* 2-cell stage rosettes (right). Nuclei (DAPI; blue). Scale bars, 10 μm.](gr4){#fig4}

![DIDO Associates with and Is Phosphorylated by PKCiota\
(A) PKCiota phosphorylation of DIDO peptide MDDKGHLSNEEAPK on residue Ser8. Top: electron transfer dissociation (ETD) tandem mass spectrometry (MS/MS) spectrum of the *m*/*z* 551.1 ion corresponding to the phosphorylated peptide; pS indicates a phosphorylated serine residue. Bottom: ETD MS/MS spectrum of the *m*/*z* 524.5 ion corresponding to the non-phosphorylated peptide. Peptide sequences are shown with the identified c-/z-type ions.\
(B) Left: anti-HA immunoprecipitates of a negative control, WT HA-DIDONT, HA-DIDONTSer8Ala, shortened HA-DIDONT, and anti-aPKC as positive control were used as substrates in an in vitro kinase assay with recombinant PKCiota and zeta; autoradiograph shows \[^32^P\]ATP incorporation (arrowheads). Right: western blot controls of lysates and precipitates of corresponding proteins.\
(C) Labeling of centrosomes (arrowheads) in WT 2-cell stage rosettes with γ-TUBULIN (red) and DIDO MAB-1C6 (green; nuclear only).\
(D) Labeling of centrosomes (arrowheads) in WT 2-cell stage rosettes with PAB-DIDO3 (green) and γ-TUBULIN (red).\
Scale bars: (C and D) 10 μm.](gr5){#fig5}

![DIDO1 Interacts with WWP2 in PE Formation\
(A) Left: WT d4EBs stain positive with anti-WWP2 (red) at apical membrane of OCT4 (green)-negative PE cells. Right: overlapping staining of DIDO1 (cyan) with WWP2 (red) on PE cells of WT d4EBs. Scale bar, 50 μm.\
(B) WWP2 co-immunoprecipitated with HA-DIDO1 or HA-DIDONT, but not with HA-DIDO3CT.\
(C) Co-staining of d4EBs with OCT4 (green) and PE markers FOXA2 (red) and DIDO1 (cyan) in WT d4EBs infected with shRNA-*Co* (top row) or two clones of shRNA-*Wwp2* A and B (center and bottom rows, respectively). Clone A completely lacked PE formation and clone B showed aberrant co-expression of OCT4 and FOXA2 in PE cells (zoomed images 1 and 2). Nuclei (DAPI, blue). Scale bars for EBs, 50 μm.](gr6){#fig6}

![DIDO3 Binds to the *Dido* Gene and Interacts with RNA POL II\
(A) Image of the 55-kb genomic region containing the three alternatively spliced isoforms of the *Dido* gene. HA-DIDO3 ChIP-seq binding sites (red boxes); chromatin status is reflected by individual tracks of histone modifications H3K4me3, H3K9ac, H3K27ac, H3K4me1, H3K36me3, H3K27me3, and H3K9me3 (ChIP-seq data from mouse ENCODE project); individual tracks from ChIP-seq data for RNA POL II unphosphorylated, Ser5, Ser2, or Ser7 phosphorylated ([@bib6]).\
(B) Top: DIDO3, HA-DIDO3, and DIDO3ΔCT expression in lysates of WT, mutant ESCs reconstituted with HA-DIDO3, and mutant ESCs (left) and in anti-RNA POL II co-immunoprecipitates (right), developed with anti-DIDO (MAB-1C6). Bottom: expression of total RNA POL II in the same lysates (left) and in anti-DIDO co-immunoprecipitates (right), developed with anti-RNA POL II.\
(C) qPCR data demonstrating x-fold ChIP enrichment for anti-HA-DIDO3 and -RNA POL II on *Dido* proximal promoter (right) and *Dido* internal sequence after *Dido1* 3′ UTR (left) relative to negative control (Co; immunoglobulin G), normalized to input amounts. Data are shown as mean ± SD (n from at least three independent experiments).](gr7){#fig7}
